{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45","upperLimit":"84","value":"67"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"14","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"For Cohorts A and B: Immune-related Objective Response Rate (irORR) is defined as the percentage of patients achieving a complete response (irCR) or partial response (irPR) based on irRC criteria. Per irRC criteria, Complete Response (irCR) is the disappearance of all target lesions, Partial Response (irPR) is a decrease in tumor burden by 50% or greater by a consecutive assessment at least 4 weeks after first documentation.","dispersionType":"95% Confidence Interval","groups":[{"description":"MK-3475: MK-3475 10 mg/kg every 14 days","id":"OG000","title":"Cohort A: MSI Positive Colorectal Cancer"},{"description":"MK-3475: MK-3475 10 mg/kg every 14 days","id":"OG001","title":"Cohort B: MSI Negative Colorectal Cancer"}],"paramType":"NUMBER","populationDescription":"It was a pre-specified objective to complete this objective in Cohort A and B only. Per protocol during stages 1 and 2, the study enrollment goal was 25 for Cohort A and B. However, only 24 subjects were enrolled in Cohort A. Additional subjects for this study were enrolled during the second expansion portion of this protocol.","reportingStatus":"POSTED","timeFrame":"28 months","title":"Immune-related Objective Response Rate in MSI Positive and Negative Colorectal Adenocarcinoma Participants Using Immune Related Response Criteria (irRC) During Stages 1 and 2","type":"PRIMARY","unitOfMeasure":"percentage of participants"}